Abstract Pharmacological approaches to treat breast cancer metastases in the brain have been met with limited success. In part, the impermeability of the blood brain barrier (BBB) has hindered delivery of chemotherapeutic agents to metastatic tumors in the brain. BBB-permeable chemotherapeutic drugs are being developed, and noninvasively assessing the efficacy of these agents will be important in both preclinical and clinical settings. In this regard, dynamic contrast enhanced (DCE) and diffusion weighted imaging (DWI) are magnetic resonance imaging (MRI) techniques to monitor tumor vascular permeability and cellularity, respectively. In a rat model of metastatic breast cancer, we demonstrate that brain and bone metastases develop with distinct physiological characteristics as measured with MRI. Specifically, brain metastases have limited permeability of the BBB as assessed with DCE and an increased apparent diffusion coefficient (ADC) measured with DWI compared to the surrounding brain. Microscopically, brain metastases were highly infiltrative, grew through vessel co-option, and caused extensive edema and injury to the surrounding neurons and their dendrites. By comparison, metastases situated in the leptomenengies or in the bone had high vascular permeability and significantly lower ADC values suggestive of hypercellularity. On histological examination, tumors in the bone and leptomenengies were solid masses with distinct tumor margins. The different characteristics of these tissue sites highlight the influence of the microenvironment on metastatic tumor growth. In light of these results, the suitability of DWI and DCE to evaluate the response of chemotherapeutic and anti-angiogenic agents used to treat co-opted brain metastases, respectively, remains a formidable challenge.
Introduction
Breast cancer is one of the leading causes of cancer mortality worldwide, and advances in treating primary tumors of the breast have significantly improved patient outcome in recent decades [1] . Surgical, biological and chemotherapeutic agents along with advances in early detection methods have prolonged survival of patients with breast cancer. However, an unfortunate consequence of the improved survival is the increased incidence of breast cancer metastases, and most patients will ultimately succumb to metastatic disease [2, 3] . Although there has been some progress in reducing the development of new metastatic lesions, treatment of existing metastatic breast cancer has been largely ineffective [4] . Therefore, due to the increasing burden of breast cancer metastases, a better understanding of metastatic tumor colonization is important. In this regard, animal models of metastatic disease have been used to test treatment strategies in preclinical settings and have shed light on the complex nature of metastatic tumor formation and progression.
Breast cancer preferentially metastasizes to the lung, liver, bone, lymph nodes, and brain [5] . The central nervous system (CNS) is unique among these organs in that it is considered a sanctuary site for metastases [6] . In animal models of metastatic breast cancer to the brain, tumor cells preferentially grow through co-option of the existing vasculature [7, 8] . As a result, the co-opted brain vasculature remains relatively impermeable compared to metastatic sites in other organs [9] . Thus, delivery of biological and chemotherapeutic drugs to metastases has proven problematic [9, 10] . Moreover, the lack of neovascularization in co-opted tumors precludes the use of angiogenesis inhibitors to restrict tumor growth [11] . As a consequence, treatment of human breast cancer brain metastases has been largely ineffective [12] [13] [14] . BBB-permeable variants of chemotherapeutic agents are one approach to circumvent the limited vascular accessibility [10] . By comparison, extracerebral breast cancer metastases typically manifest as solid tumor masses. Considerable progress has been made in the treatment of extracerebral metastases using both chemotherapeutic [15] and anti-angiogenic therapies [16] due to the vascular accessibility of these tumors to the drugs.
Magnetic resonance imaging (MRI) is the most widely used modality to evaluate treatment efficacy in tumors of the brain. Conventionally, tumor dimensions or volumes are considered primary endpoints as specified by the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines [17] . However, advanced MRI techniques, including diffusion-weighted imaging (DWI) and dynamic contrast enhanced (DCE) MRI, complement volumetric measures by probing physiological features not appreciated by size alone. The apparent diffusion coefficient (ADC) measured with DWI has shown promise as a biomarker of chemotherapy and is sensitive to a tumor response days to weeks before a change in volume [18] . ADC is a marker of tumor cellularity in both humans [18] and rodent models [19] and is therefore an indicator of apoptosis and necrosis following effective cytotoxic therapy. Likewise, DCE is a biomarker of vascular changes that occur the absence of changes in tumor size [20] . DCE measures the vascular permeability that is altered by successful anti-angiogenic therapy. Although these MR metrics have yet to be fully validated [21] , both techniques have demonstrated considerable promise in primary brain tumors. However, there has been a relative paucity of DCE and ADC measurements in metastatic brain tumors, despite the fact that the incidence of brain metastases outnumbers primary brain tumors by a factor of 10 [2] .
We applied DWI and DCE MRI in a rat model of metastatic breast cancer [22] to determine the ADC and DCE features of metastatic breast tumors in the brain. Moreover, we sought to evaluate the potential differences between metastatic tumors situated in either the brain or bone since they are known to have significant microstructural differences. The results demonstrate that the microenvironments of metastatic tumors impart divergent microscopic growth patterns, and these features relate to distinct physiological and structural differences as measured by DCE and ADC MRI, respectively. Compared to metastatic sites in the bone, in which tumors developed as solid, expansive masses with high vascular permeability, the co-opted brain metastases had a limited permeability to gadolinium contrast agent. Moreover, brain metastases were associated with extensive interstitial edema in the infiltrated parenchyma. Microscopic evidence of acute injury in the form of beaded axons and dendrites was observed, and the subsequent degeneration of injured neurons was a likely cause of the continual elevations of ADC with prolonged growth. The results indicate that there may be significant challenges in using these ADC and DCE MRI to evaluate promising therapies in preclinical models.
Materials and methods

Tumor cell line
MDA-MB-231-BR-eGFP cells (a gift from Dr. Diane Palmieri [6] ) were cultured with DMEM growth media (Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum and 1% penicillin streptomycin antibiotics at 37°C in a 5% CO 2 conditioned incubator [22] .
Animal procedures
All studies were approved by the Animal Care and Use Committee at our institution. Twelve, 6-8 week old NIHrnu rats (Charles River, Wilmington, MA) received 10 6 MDA-MB-231-BR-eGFP (231BR) cells by intracardiac (IC) injection. Rats were anesthetized with 2-3% isofluorane in 100% O 2 . A 200 ll suspension of 10 6 tumor cells in 10 units/ml heparin in PBS was delivered into the left ventricle through a 27-gauge needle under real time ultrasound guidance using a 14 MHz linear probe (Acuson Sequoia C256, Siemens Medical Solutions, Malvern, PA). Rats underwent MRI prior to injection (baseline), 1 day post-injection, and weekly thereafter for 5 weeks. Rats were anesthetized with isofluorane delivered through a nosecone. Body temperature was maintained at 37°C using a circulating warm water pad. Animals were euthanized after the final imaging session or if they exhibited any evidence of significant weight loss ([20%), neurological changes such as paraplegia, or apparent pain or weakness in limbs.
Magnetic resonance imaging
In vivo MRI was performed on a 7 T Bruker Biospec (Billirica, Ma) using a 40 mm quadrature volume coil (Doty Scientific, Columbia, SC). For diffusion weighted imaging, a multiple-echo spin-echo sequence was used to acquire three non-weighted images and 15 diffusionweighted images [23] with a b-value of 1,000 s/mm 2 and parameters: D = 10 ms, d = 4 ms, TR = 2250 ms, and TE = 20 ms. For DCE-MRI, T1-weighted gradient echo images (TR = 600 ms, TE = 10 ms) were acquired with variable flip angles (5, 10, 20, 30, 45, 60, 75 , and 90) prior to and 13 min after the start of the dynamic series. Dynamic T1-weighted images were acquired during a bolus injection of 0.3 mmol/kg Gadolinium-dimeglemine (Gd-DTPA, Magnevist, Bayer-Schering Pharma, NJ) through the lateral tail-vein with the following parameters: TR = 600 ms, TE = 10 ms, flip angle = 60°, and temporal resolution = 12 s. Sixty time-points were acquired and the injection occurred on the 9th time-point. All datasets were acquired with 15 axial slices at a thickness of 0.5 mm and a matrix size of 128 9 128, yielding an inplane resolution of 234 lm 2 .
Data analysis
Images were reconstructed using custom software written in Matlab (Mathworks, Natick, MA). Parametric maps of the diffusion tensor, including the ADC (ADC = k 1 ? k 2 ? k 3 )/3), were computed where k 1 , k 2 , and k 3 represent the eigenvalues following tensor diagonalization. DCE-MRI analysis was performed by calculating the pre-injection T 1 relaxation time constant on a pixel-by-pixel basis from the variable flip-angle gradient echo images [24] . The signal intensity of the dynamic T 1 -weighted imaging series was converted to the change in T 1 (DT 1 = TR/ln(1 -S i /S 0 ), where S 0 is the pre-injection signal intensity and S i is the post-injection change in intensity at the ith time-point. DT 1 was subsequently converted to concentration of contrast agent [25] ([Gd] = DT 1 /r 1 in mM) [26] where r 1 is the relaxivity of Gd-DTPA in blood plasma at 7 T (3.3 (mmol/ l) -1 s -1 ) [27] . A non-model-based approach was used for visualization and quantification. Maps of the initial area under the gadolinium curve (IAUGC) were derived by integrating [Gd] for the first 90 s (8 timepoints) following the bolus injection.
T 2 -weighted images were registered to a common template using AIR 5.2.5 [28] and transformations were applied to the ADC and IAUGC90 parametric maps. Both brain and bone metastases underwent a region of interest (ROI) analysis and were manually circumscribed on T 2 -weighted images at each time point. A subset of brain metastases were not visible on T 2 -weighted or ADC images, but focal enhancement was seen on IAUGC90 maps, and these lesions were manually circumscribed on the postcontrast T 1 maps. Metastases that were obviously meningeal were not included in the quantitative analysis. The largest diameter (LD) was derived from the circumscribed tumors using the Feret's diameter measurement in ImageJ.
Functional diffusion maps (fDM) were created according to established methods [19] . Two successive ADC measurements in four control animals were used to derive the fDM threshold. A whole-brain mask was created by manually tracing the brain on the registered and averaged ADC maps, with regions near the ventricles and brain surface excluded. The pixel-by-pixel scatter plots from the two time-points yielded a mean ADC of 0.77 9 10 -3 mm 2 /s and a 95% confidence interval of ±0.39 9 10 -3 mm 2 /s. Brain metastases were first segmented at week 4 and used for the subsequent comparison between week 4 and week 5. Voxels with an ADC increase greater than the fDM threshold between baseline and week 4 were segmented, and only individual metastases larger than 275 lm 3 (20 interconnected voxels) at week 4 were included. Twenty-four brain metastases survived the segmentation and were used for the subsequent fDM analysis. Four bone metastases were visible on T 2 -weighted images at week 4 and were manually segmented for inclusion in the fDM analysis. The fDM analysis consisted of calculating the fractional volume of voxels greater than or less than the fDM threshold separately for each tumor.
Histopathology
Perfusion-fixed brains were excised, immersed in 4% paraformaldehyde overnight, cryoprotected in a sucrose gradient, frozen in liquid nitrogen, and sectioned at a thickness of eight microns. Immunofluorescence and hematoxylin and eosin (H&E) staining was performed as previously described [22] . Primary antibodies included anti-human CD44 (Abcam) or anti-human b1-integrin (Abcam) to identify MB231 cells and anti-rat Tusc5 (Genway), SMI31 (Covance), and MAP2 (Invitrogen) to identify endothelial cells, neurofilamants, and microtubules, respectively. Briefly, slides were rinsed with phosphate buffered saline (PBS), incubated with blocking serum for 5 min, and incubated with the primary antibody (1:200 dilution) at 4°C overnight. Sections were washed 39 with PBS, incubated with the secondary antibody (1:200 dilution) for 30 min at room temperature, rinsed 39 in PBS, and cover-slipped with VectaShield with 4 0 ,6-diamidino-2-phenylindole (DAPI). Slides were imaged using brightfield or fluorescence microscopy (Zeiss Axio, Carl Zeiss Microimaging GmbH, Germany). Two percent Evans Blue dye was injected intravenously in a single animal containing both leptomenengial and parenchymal brain metastases just prior to euthanasia and perfusion fixation. Histological sections were prepared and extravasated dye was directly imaged using an excitation wavelength of 540 nm [29] .
Statistical analysis
Statistical analysis was performed using Prism (GraphPad Software, La Jolla, CA). A student's t-test was used to compare ADC, IAUGC90, and fDM values between brain and bone metastases or between brain metastases and the normal appearing brain. A Pearson's coefficient was used to correlate ADC, IAUGC90, and LD values. A one-way ANOVA was used to assess the temporal progression of tumor ADC and volumes, and if the overall model was significant, individual post-hoc tests were performed using a Bonferroni correction for multiple comparisons. A onesample t-test was used to compare fDM volume fractions to the theoretical value of 5%. A p-value of 0.05 (two-tailed) was considered significant for all tests.
Results
Intracardiac delivery of MDA-MB-231BR-eGFP cells resulted in metastatic lesions developing within both the brain and bone by 4 weeks post injection. Metastases developing in these two different sites displayed disparate morphologies. Out of 12 animals receiving 231BR cells, 164 brain metastases were identified in seven animals at week five as hyperintensities on the T 2 -weighted (Fig. 1a) . No distinction was made between metastases within the brain parenchyma or leptomenengial metastases based on the MR images. Brain lesions displayed increased diffusivity compared to the surrounding cortex as shown by the ADC maps (Fig. 1a) . On brightfield and fluorescent microscopy, brain metastases displayed a clear co-opted morphology, with nearly all breast cancer cells growing within a few cell layers of the existing vasculature. These co-opted metastases were associated with cytotoxic edema or necrosis visualized as enlargement of the extracellular space surrounding the tumor cells. Bone metastases were evident on T 2 -weighted images as masses with high signal intensity compared to the surrounding muscle and appearing to originate from within the trabecular marrow spaces (Fig. 1b) . Eleven bone metastases were observed in the temporal bone and mandibular joint on the MR images in five animals, since these regions were observable in the acquisition of brain MRI. ADC values of bone metastases were comparable to the normal brain. Histologically, bone metastases were hypercellular, solid masses with well-circumscribed margins.
Metastatic sites in the brain and bone exhibited different physiological characteristics. Permeability was assessed using the semi-quantitative parameter initial area under the gadolinium curve (IAUGC90) derived from DCE-MRI. In co-opted brain metastases, there was limited or no extravasation of a low molecular weight gadolinium contrast agent (Fig. 2a) and indicated a relatively intact blood brain barrier (BBB). A fraction of brain metastases were not observable on T 2 -weighted images or ADC maps, but exhibited substantial leakage of gadiolinium chelate in what appeared to be within the brain parenchyma on MR images (Fig. 2b) . Microscopic examination revealed that many of these metastatic lesions were situated in the leptomenengies or sulci of the cerebellum. The morphology of tumors residing in these regions were similar to those of the bone and were hypercellular masses without evidence of co-opting extracerebral vessels. The example in Fig. 2b did not invade the parenchyma, but occasionally, metastases spanned both environments with an infiltrative morphology in the parenchyma and a solid mass-like morphology outside of the parenchyma. Metastases situated in the meninges (Fig. 2c) or the bone (Fig. 2d) were highly permeable as evidenced by the substantial leakage of intraveneous gadolinium chelate and had ADC values comparable to the normal brain. Both of these metastatic sites promoted the development of hypercellular masses.
A quantitative region of interest analysis (Table 1) was performed on all 164 brain metastases and 11 bone metastases manually identified on the T 2 -weighted images at 5 weeks post-injection (Fig. 3) . Metastases situated in the brain had significantly greater ADC values (1.30 ± 0.22 lm 2 /ms; mean ± S.D.) compared to either the normal brain (0.77 ± 0.04 lm 2 /ms; P \ 0.0001) or bone metastases (0.94 ± 0.06 lm 2 /ms; P \ 0.0001). Brain metastasis had significantly lower IAUGC90 (0.03 ± 0.03 [Gd]*s) than bone metastases (0.19 ± 0.03 [Gd]*s; P \ 0.0001) and significantly greater IAUGC90 than that of the normal brain (0.008 ± 0.003 [Gd]*s; P = 0.006). ADC and IAUGC90 had a significant inverse correlation (Table 2) in brain metastases (R 2 = 0.369; P \ 0.0001) but not in bone metastases (R 2 = 7.0 9 10 -6 ; P = 0.99). Brain metastases size (largest diameter) had a significant, but low correlation with ADC (R 2 = 0.065; P = 0.001) and was not correlated with IAUGC90 (R 2 = 6.0 9 10 -6 ; P = 0.98). The size of bone metastases was significantly correlated with permeability (R 2 = 0.793; P \ 0.0001) but not with ADC (R 2 = 0.086; P = 0.38). In a slice-matched ADC and histological section, several large metastases were readily identified on both images (Fig. 4a, b) . However, the edema detected with ADC underestimated the extent of tumor infiltration. Moreover, many smaller metastases were seen on the histological section that were not observed on the ADC map. This is likely a consequence of the relative size of an MRI voxel (234 9 234 9 500 lm) compared to the histological section (8 lm thick) but is also complicated by both T 2 -weighted images and ADC maps being sensitive to the increased edema surrounding the metastatic cells, and not the cells themselves. The edema is visible on histological sections as increases in the extracellular space surrounding the co-opted MB231 cells (Fig. 4c) . Compared to neurofilament staining (SMI31) for axons, MAP2 staining of dendrites qualitatively demonstrated a decrease in fluorescent intensity in the dendrites surrounding the infiltrating tumor cells (Fig. 5a, b) . Moreover, MAP2-stained dendrites demonstrated a beaded morphology suggestive of acute injury (Fig. 5c, d) . Correspondingly, decreased neuronal cell density was observed in the central region of the metastases (Fig. 5e ) compared to the periphery and normal brain (Fig. 5f ). In the animal administered intravenous Evans blue, dye extravasation was seen in a leptomenengial metastasis (Fig. 5g) , but not in the infiltrative, parenchymal portion of the same tumor or in a separate lesion (Fig. 5h ).
Brain and bone metastases exhibited differential growth kinetics from weeks 3 to 5 (Fig. 6) . Specifically, the ADC values of bone metastases were not significantly different throughout weeks 3-5 (F = 2.47; P = 0.12). In contrast, the ADC measured in brain metastases continued to increase through time (F = 32.0; P \ 0.0001), increasing significantly from week 3 to week 4 (t = 6.0; P \ 0.001) and from week 4 to week 5 (t = 3.2; P \ 0.01). Both brain (F = 15.56; P \ 0.0001) and bone (F = 5.76; P = 0.013) metastases exhibited significant increases in volume over the 2 weeks studied.
The functional diffusion map method of analysis was performed to identify the ADC changes on a pixel-by-pixel basis (Fig. 7) . Brain metastases were first segmented from week four images. Pixels with a significant increase in ADC at week 4 compared to pre-injection values were included and interconnected pixels greater than 275 lm 3 were considered as individual tumors (Fig. 7a) . The 24 separate brain metastases surviving the segmentation exhibited a significantly greater positive than negative fDM fraction from weeks 4 to 5 (t = 5.8; P \ 0.0001). Whereas the positive fDM fraction was significantly greater than the theoretical 5% change expected from two successive measurements (t = 5.3, P \ 0.0001), the negative fDM fraction was significantly less than 5% (t = 5.03, P \ 0.0001). In the four bone metastases present at week 4 ( Fig. 7b) , by comparison, the positive or negative fDM fractions from weeks 4-5 were not significantly different from one another (t = 2.3; P = 0.10), nor were they significantly different than the theoretical 5% (pos fDM: t = 2.9, P = 0.06; neg fDM: t = 0.06, P = 0.96).
Discussion
Noninvasively assessing cancer therapies is important for patient management and as outcome measures in clinical trials and preclinical drug development. In primary tumors of the brain, DCE-MRI and ADC have shown increased /s), IAUGC90 ([Gd]*s), LD-Largest Diameter (mm). * T and P-values based on a two-sample t-test comparing brain and bone metastases sensitivity to the effects of anti-angiogenic and chemotherapeutic agents, respectively, compared to measurements of tumor volume. However, their application to metastatic tumors in the brain has received considerable less attention despite the greater incidence of brain metastases, in part, because brain metastases have a poor response to existing pharmacologic treatments. Preclinical models of metastatic disease have provided a platform for the development and testing of newer treatment strategies, and MRI of such models is equally well suited to accelerate discovery. Therefore, we examined the natural progression of DCE-MRI and ADC in a rat model of breast cancer metastases to the brain and bone to determine the utility of these techniques in preclinical drug discovery. Our results demonstrate substantially different pathologies and physiologies of metastases situated in either the brain or bone. Metastases in the bone were highly permeable and had stable ADC values over time, reflecting the microscopic morphology of well-vascularized, solid tumor masses. These properties make treatments with anti-angiogenic and chemotherapeutic agents feasible, and DCE-MRI and ADC are amenable to monitor the efficacy of such treatments, respectively. In MDA-MB-231 breast cancer bone metastases treated with anti-angiogenic therapy, permeability changes were evident with no change in cellularity, as measured with ADC, as expected [30, 31] . By comparison, in both animal [32] and human [33] prostate cancer metastases to the bone, ADC was an indicator of responsiveness to cytotoxic therapy.
In the current study and others, MB231BR brain metastases grew through co-option of the existing vasculature. DCE-MRI demonstrated that the BBB had limited, although heterogeneous permeability in co-opted tumors, consistent with previous reports [34, 35] . The permeability of MB231 brain metastases has been previously evaluated in mice using post-mortem analyses of tracer uptake [9, 10] . Despite the differences in technique, the 3.5-fold increase in permeability in brain metastases compared to the normal brain as measured with DCE MRI is consistent with those studies. Moreover, the co-opted growth of brain metastases caused extensive edema of the invaded parenchyma in the form of enlarged extracellular spaces. As a consequence of the additional free water content, ADC measurements were elevated in metastases compared to the surrounding normal brain. High ADC values were also reported in human cerebral metastases originating from the lung or breast [36, 37] . In the current study, ADC increased with continued tumor growth as measured with both an ROI analysis and a pixelwise fDM analysis. Since ADC increases are typically associated with tumor cell apoptosis and necrosis following cytotoxic therapy, the increased ADC with normal tumor growth may limit the ability of DWI to monitor effective cytotoxic therapy in co-opted tumors in the brain.
The MDA-MB-231BR ''brain-seeking'' breast cancer cells preferentially metastasize to the brains of rats and mice following delivery to the peripheral circulation [38] , although previous work has shown that bone metastases are equally possible [22, 39] . Our results and those of others [40] have demonstrated that highly vascularized tissues, such as the brain, promote the co-opted growth pattern of breast cancer micrometastases [7, 8] . Although co-opted tumor growth is independent of angiogenesis [11] , and angiogenesis is often associated with insufficient oxygen supply, it is tempting to relate vessel co-option as means of maintaining partial pressure of oxygen. However, vessel co-option of MB-231BR cells appears to be regulated by molecular cues in the basement membrane, including b1-integrin, which promotes infiltrative and invasive growth [7, 41] . As demonstrated in this study, although different microenvironments are equally hospitable for tumor cell replication, these same microenvironments cause vastly different pathologies and physiologies measured with microscopy and MRI, respectively. The finding that co-opted breast cancer brain metastases causes injury to the surrounding neurons is important. Previous studies with the same breast cancer cell line demonstrated a lack of caspase-3-positive, apoptotic cells surrounding metastases [42] . As shown in Fig. 5 , neuronal densities were decreased in metastases, and MAP2 stained Beading is a consequence of acute hypoxic or excitotoxic injury in dendrites [43] , but it is unknown whether the injury shown herein is a consequence of either, or both, mechanisms. Excitotoxic injury is most often associated with excessive release of the excitatory neurotransmitter glutamate. It has been implicated in the invasiveness and neuronal injury associated with gliomas [44, 45] , and although MB-231 cells release glutamate [46] , it is unknown whether they do so in sufficient concentrations to promote neuronal injury and death [47] . An alternative mechanism of neuronal injury may be caused by the physical nature of co-opted growth, which is known to occlude vessels [48] or induce vascular remodeling [49] . These physical changes could reduce blood flow and create ischemic conditions, and this is consistent with the notion that hypoxia induces death in neurons but promotes invasiveness of MB-231 cells [50] . The effects of metastatic growth on the integrity and functionality of neurons certainly warrants further investigation. Both T 2 -weighted and ADC images are sensitive to the consequences of tumor growth in the brain (edema) and are not a direct marker of tumor cells, despite the demonstrated correlation between cellularity and ADC for solid tumors of the brain and body [51, 52] . Consequently, these MRI indices clearly underestimate the extent and number of brain lesions compared to corresponding histological sections (Fig. 4) . Volumetric measurements made according to the RECIST criteria have been used as outcome measures in clinical trials of breast cancer metastases in the brain [12, 14] , lung [53] , liver [53] , and bone [41] . However, more sensitive techniques are needed to accurately monitor the extent of highly invasive tumors of the brain [54] . The sensitivity, or lack thereof, of MRI to infiltrative lesions is also a consideration when assessing the issue of tumor dormancy [55] , as co-opted micrometastases may be undetectable with MRI due to the low cellular density and minimal edema. Among the potential methods to improve sensitivity, intravascular superparamagnetic iron oxide nanoparticle based MRI contrast agents have shown promise in detecting BBB-impermeable brain tumors [56] .
An important consideration of all preclinical models is the applicability to the human situation. Regarding the MRI outcome measurements, both DCE-MRI and DWI have been shown to be similarly effective in numerous animal models and humans cancers. Aside from the considerations of improved signal-to-noise ratio and therefore higher resolution of preclinical MRI, DCE-MRI and DWI are directly translatable to clinically relevant field strengths of 1.5 and 3 T compared to the 7 T animal scanner used in the current study. ADC measurements are independent of field strength and have been widely applied to the study of cancers. DCE-MRI has benefits to being performed at lower field strengths, owing to the increased longitudinal (r 1 ) relaxivity of gadolinium agents at lower magnetic fields. However, the use of either model-based or modelfree approaches to analyze DCE-MRI data is the subject of debate [25] . While substantial efforts have been made to obtain quantitative measurements of transfer coefficients and permeability using pharmacokinetic modeling, these model-based approaches are not without certain assumptions and limitations. On the other hand, model-free measurements, such as the IAUGC90 used in the current study, are a non-specific combination of vascular permeability, blood flow, and fractional interstitial volumes, and therefore have their own limited interpretability. Nonetheless, our intention in the current study was to demonstrate the relative permeability of metastases within two different Fig. 6 Differential growth kinetics of metastases situated in the brain or bone. Brain metastases, depicted on ADC maps, increase in both size and the number from weeks 3-5 post-injection. The MRI-defined tumor margins expanded at a greater rate in bone metastases than in brain metastases. The ADC of bone metastases remained stable over the course of disease, but the ADC of brain metastases continued to increase over time sites detected within the same animal. Therefore IAUGC90 is adequately suited for that purpose. The inter-tumor heterogeneity of IAUGC90 measurements are likely the result of true physiological differences, since the control measurements in the muscle were highly consistent among animals. Since model-free DCE measurements are often sufficient in clinical situations, the results of the current study are directly relevant to brain metastases in humans.
Conclusions
The results in the current study demonstrate that breast cancer metastases growing through vessel co-option in the brain exhibit increases in ADC (and fDM) that are typically interpreted as a clinical treatment effect (i.e., cytotoxic killing) in primary brain tumors. The changes in the current study are associated with injury to the surrounding neurons suggestive of acute hypoxia, excitotoxicity, or both, as a result of tumor expansion. The clinical applications of such findings are that using ADC to monitor patients with metastatic disease in the brain in therapeutic trials would first require validation in imaging-based clinical trials. Moreover, neuroprotective strategies may be added to chemotherapeutic regimes in the treatment of metastatic breast cancer in the brain in order to minimize collateral damage to the infiltrated brain tissue. Finally, we demonstrated the limited degree of BBB disruption in breast cancer brain metastases, and this may preclude the use of anti-angiogenic drugs in co-opted tumors of the brain. 
